Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Utari et al. (2010) asked parents of children with fragile X syndrome about the antibiotic minocycline. They wanted to know what side effects showed up and if parents saw any language or behavior changes.

The team mailed a short survey. Parents wrote in what they noticed while their child took the drug. No lab tests or clinic visits were required.

Most families reported stomach pain, diarrhea, or nausea. Despite the tummy trouble, many parents also said their child spoke more words or acted calmer.

The study has no control group, so the gains could be chance or placebo. The authors stress that real trials are still needed.

Pitchford et al. (2019) later showed parents can run the Early Start Denver Model at home and hit high fidelity scores. Their work extends Agustini’s call for feasible outcome tools by proving parent-delivered measures work in the same population.

Hall et al. (2022) used telehealth to coach parents through functional communication training. Three-year follow-ups still showed big drops in irritability. This mirrors Agustini’s parent-report style but gives controlled, long-term data Agustini lacked.

Johnson et al. (2009) tested another brain drug, memantine, in an open-label case series just like Agustini. Both papers list parent impressions and drop-outs, showing the field keeps using weak designs until RCTs arrive.

You will hear families ask about minocycline. This paper tells you the main risk is GI upset and any benefit is still unproven. Use the parent-report ideas from Agustini, but copy the better designs in Hall et al. and Pitchford et al. (2019) when you track progress. Push for medical oversight and keep behavior data tight.